SickKids Industry Partnerships & Commercialization (IP&C)

Innovative discoveries in #healthcare have the power to transform the lives of patients. The Industry Partnerships & Commercialization (IP&C) office at SickKids is a catalyst for innovation in paediatric health care. Through strategic partnerships with industry leaders, academia and the broader health ecosystem, IP&C facilitates the translation of ground-breaking research into tangible solutions that can improve the lives of patients worldwide. Discover the pivotal role IP&C plays at SickKids in advancing innovation. From ideation to commercialization, IP&C’s team of business professionals are passionate about amplifying the impact of innovation efforts and driving SickKids’ research institute’s mission forward. https://lnkd.in/gc8zHevw Ihor Boszko Konrad Powell-Jones Oksana Goncharenko Stephanie Tammam Anita A. Cloutier Jevin Francis Sedric Pankras Karin A. Kamran Rezai Iasha C. Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® The Hospital for Sick Children

👏 A Big Thank You to Our SickKids PoP Grant Competition Panelists! We’d like to extend our deepest thanks to the commercial and scientific reviewers who helped make this year’s Proof of Principle Grant Competition such a success: Commercial Reviewers: ▪ Jeremy Bridge-Cook, Genomadix ▪ Megan Dover, P.Eng., MBA, Cross-Border Impact Ventures ▪ Evelyn Pau, PhD, Amplitude Ventures ▪ Suman Rao, PhD, Lumira Ventures Scientific Reviewers from The Hospital for Sick Children ▪ Greg Beilhartz, Molecular Medicine ▪ Michelle Maxson, Ph.D., Cell Biology ▪ Lauryl Nutter, Genetics & Genome Biology ▪ Amy W. Developmental & Stem Cell Biology Your dedication and expertise are critical to transforming discoveries into real-world healthcare solutions. Thank you for being part of this journey! ➡ A special shoutout to Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® for coordinating this year's competition and the entire IP&C team for their hard work behind the scenes! ___ ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

🎉Announcing the Winners of the SickKids Proof of Principle (PoP) Grant Competition! 🎉 We’re thrilled to share the recipients of this year’s PoP Grant Competition, whose groundbreaking #SKInnovation are one step closer to commercialization. These projects are set to make a lasting impact on healthcare with their cutting-edge research and innovative solutions. 🏆Christine Bear, for the project titled “Comparison of SickKids CFTR Potentiator to Ensifentrine in Ameliorating COPD in In-Vitro and In-Vivo Models” 🏆Jayne Danska, for the project titled “Platform Conversion of Novel Antibody Biomarkers for Type 1 Diabetes and Patient Response to Preventative Immunotherapy” 🏆Lynne Howell, for the project titled “In Silico Designed Glycoside Hydrolases for Treatment of Biofilm Infections” Congratulations! We’re excited to watch these projects advance towards commercialization, bringing innovative solutions to the forefront of health-care. ➡ Read the full story here: https://lnkd.in/gwPeWJbR ___ ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

💡 IP&C’s Proof of Principle (PoP) Grant Competition Pitch Day is underway! Co-chaired by Ihor Boszko (Executive Director, IP&C) and Roman Melnyk (Senior Scientist, Molecular Medicine at SickKids), our esteemed panel of commercial reviewers—Jeremy Bridge-Cook (Genomadix), Megan Dover, P.Eng., MBA (Cross-Border Impact Ventures), Evelyn Pau, PhD (Amplitude Ventures), and Suman Rao, PhD (Lumira Ventures)—alongside scientific reviewers from The Hospital for Sick Children, will evaluate projects tackling challenges such as neurodevelopmental disorders, cystic fibrosis, traumatic brain injury, and more. Designed to advance promising #SKInnovation into commercial products, selected projects will receive translational funding and support to take the next steps toward patient impact. 📢 Stay tuned for the funding recipient announcements later this week!   To learn more about the PoP competition and how it’s driving the future of health innovation, visit: https://lnkd.in/gC5a5jTN _____ ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

IP&C's Licensing Associate, Jevin Francis, helped coordinate a site visit to Dr. Dale Podolsky, MD, PhD, FRCSC's lab at The Hospital for Sick Children! Our partners at TIAP got a first-hand look at #SKInnovation, including the first minimally invasive robotic cranial bone cutting tool for patients experiencing craniosynostosis. _____ ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

Exciting news! Dr. Christine Bear, Senior Scientist at The Hospital for Sick Children (SickKids) and Professor at the University of Toronto, has been awarded $325,125 through the Canadian Institutes of Health Research | Instituts de recherche en santé du Canada Project Grant Program to advance a novel treatment for chronic obstructive pulmonary disease (COPD). #COPD affects 300 million people worldwide, causing severe respiratory issues and accounting for over 3.2 million deaths annually. Dr. Bear’s groundbreaking #SKResearch focuses on a patented class of molecules with the potential to target and reverse mucus obstruction, a key factor in COPD pathogenesis. With this funding, Dr. Bear, alongside collaborators Dr. Robert N. Young (Simon Fraser University) and Dr. S. Vamsee Raju, B.Pharm, Ph.D (University of Alabama at Birmingham), will explore the safety and effectiveness of this promising therapy. Read more ️️➡️ https://lnkd.in/gdxMXcUg #SKInnovation #Healthcare #SickKids _____ ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

#SKinnovation continues to make headlines, this time in The Globe and Mail! Radiant Biotherapeutics, a #SickKids start-up, has raised $35 million in venture capital to accelerate the development of next-gen antibody therapies. Pioneered by Jean-Philippe Julien’s lab at The Hospital for Sick Children, alongside contributions from Bebhinn Treanor at the University of Toronto, their revolutionary #Multabody technology is poised to transform the treatment of complex diseases like cancer and HIV. ➡ Read their article here: https://lnkd.in/gVFJf3zu --- ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

📢 Radiant Biotherapeutics has closed a $35 million Series A financing co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures. This important funding will enable the company to further develop cutting-edge #Multabody therapeutics and accelerate promising drug candidates towards clinical trials. The production of next-generation therapeutics is made possible by the groundbreaking #SKResearch done by Dr. Jean-Philippe Julien at The Hospital for Sick Children and Dr. Bebhinn Treanor at the University of Toronto! Read more about Radiant Biotherapeutics: https://lnkd.in/guMJUs-z ➕Connect with the IP&C Team! Executive Director - Ihor Boszko Director of Business Development - Konrad Powell-Jones Director of Licensing and Industry Partnerships - Oksana Goncharenko Business Development and Alliance Manager - Stephanie Tammam Licensing Associate - Jevin Francis Business Development Associate - Karin Aguilar Business Development Associate - Kamran Rezai Legal Counsel - Iasha Chaudhry Administrative Coordinator - Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® IP Administrative Coordinator - Anita A. Cloutier Communications and Events Coordinator - Jocelyn Lee

#Glioblastoma (GBM) Awareness Day was initiated by the National Brain Tumor Society to support the needs of GBM patients and those working toward better treatments, quality of life, and ultimately, a cure. Xi Huang’s discovery at The Hospital for Sick Children brings us one step closer to that cure. GBM is a type of #braincancer characterized by aggressive and complex tumours that are notoriously difficult to treat. Conventional therapy lacks specificity, causing irreparable brain damage and extends patient survival by only two months on average. Xi designed a peptide that specifically targets GBM by killing tumour cells to slow its progression with no observable side effects in preclinical mouse models. The mechanism behind this therapeutic effect is the protein’s ability to disrupt a novel ion-channel complex expressed only by GBM cells. This discovery offers the potential for effective treatment against both primary and recurrent, chemoresistant GBM, as well as other tumours in which this ion-complex channel is present.   IP&C has played a crucial role in protecting Xi's methods and composition of matter by managing extensive patent applications across international jurisdictions. We are seeking investments and strategic partnerships to facilitate the development of the peptide therapy program.   To learn more about Xi’s work, read the full technology brief at https://lnkd.in/gFAg-ymM   To inquire about investment and partnership opportunities, send us a direct message or contact our Director of Business Development Konrad Powell-Jones at Konrad.powell-jones@sickkids.ca

On May 28th at the 2024 #SickKids Innovation Showcase, SickKids senior scientist Dr. Adam Shlien, was presented with the Audience Choice Award! Dr. Shlien impressed the panel of investors and attendees with his research on improving the speed and accuracy of cancer treatment using an ML-based RNA platform. As the audience choice for best technology pitch of the day, Dr. Shlien was awarded funding to further his research and development, with the goal of securing a strategic partnership to bring his innovation to market. Congratulations @Dr. Adam Shlien! The Hospital for Sick Children Adam Shlien Ihor Boszko Konrad Powell-Jones Oksana Goncharenko Stephanie Tammam Jevin Francis Kamran Rezai Karin A. Maureen Onuchuku, PMI-ACP®, CSM®, CSPO® Anita A. Cloutier